Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

(2015) Jan de Jong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia

(2015) P. Janovska et al.   CLINICAL CANCER RESEARCH

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

(2015) M. Skarzynski et al.   CLINICAL CANCER RESEARCH

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

(2015) Michael Y. Choi et al.   Clinical Lymphoma Myeloma & Leukemia

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function

(2015) Li Ren et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

(2015) Jian Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

(2014) S. E. M. Herman et al.   BLOOD

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53

(2014) J.-F. Fecteau et al.   BLOOD

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells

(2014) S. W. Hofbauer et al.   BLOOD

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

(2014) F. D. Roit et al.   HAEMATOLOGICA

Wnt5a-Rac1-NF- B Homeostatic Circuitry Sustains Innate Immune Functions in Macrophages

(2014) D. Naskar et al.   JOURNAL OF IMMUNOLOGY

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

(2014) N. L. Komarova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells

(2013) M. F. Pascutti et al.   BLOOD

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia

(2013) S. A. Rushworth et al.   BLOOD

The Planar Cell Polarity Pathway Drives Pathogenesis of Chronic Lymphocytic Leukemia by the Regulation of B-Lymphocyte Migration

(2013) M. Kaucka et al.   CANCER RESEARCH

Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells

(2013) Yichao Zhu et al.   CELLULAR SIGNALLING

Biology of Chronic Lymphocytic Leukemia in Different Microenvironments

(2013) Yair Herishanu et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

(2013) S Cheng et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44

(2013) S. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ROR1 can interact with TCL1 and enhance leukemogenesis in E -TCL1 transgenic mice

(2013) G. F. Widhopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity

(2011) R. Velaithan et al.   BLOOD

Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia

(2011) B. Mizukawa et al.   BLOOD

B-cell receptor signaling in chronic lymphocytic leukemia

(2011) F. K. Stevenson et al.   BLOOD

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Novel Combination Therapies

(2011) Janet Woodcock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

(2011) J. A. Burger   Hematology-American Society of Hematology Education Program

Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis

(2010) E. E. Bosco et al.   BLOOD

Ror2/Frizzled Complex Mediates Wnt5a-Induced AP-1 Activation by Regulating Dishevelled Polymerization

(2010) M. Nishita et al.   MOLECULAR AND CELLULAR BIOLOGY

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

(2010) Julie A Di Paolo et al.   Nature Chemical Biology

Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis

(2010) Morgan O'Hayre et al.   PLoS One

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

(2008) P. Ghia et al.   JOURNAL OF INTERNAL MEDICINE

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

(2008) T. Fukuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA